Bodenhoff Mads sold $811K of ASND

Ascendis Pharma (ASND) will present data at ASBMR 2026 showing normalization of bone mass in hypoparathyroidism patients treated with palopegteriparatide over five years. The company will also share updates on navepegritide for achondroplasia, including improved growth and physical functioning in children.

Ascendis Pharma (ASND) will present data on its hypoparathyroidism and achondroplasia programs at ASBMR 2026. Key updates include 5-year data from TransCon PTH trials showing normalized bone mass and microarchitecture. The company also plans to share results from its achondroplasia trials, including growth and physical function improvements.

Ascendis Pharma (ASND) authorized a $400M share buyback. Q2 2025 saw €315M product revenue, up 105% YoY, with €220M operating profit. Cash reserves grew to €812M. Buyback is discretionary, dependent on market conditions. YORVIPATH drove most revenue, while SKYTROFA and YUVIWEL contributed less. Costs increased due to expansion and R&D.

Ascendis Pharma (ASND) and BioMarin (BMRN) settled a patent dispute, with ASND paying BMRN royalties on Yuviwel sales. ASND rose 6% and BMRN 1%. Analysts adjusted targets but kept ratings unchanged, citing legal clarity and growth prospects.

Ascendis Pharma (ASND) fell 13% to $230.28 after authorizing a $400M share repurchase program. The stock traded between $230.18 and $257.53 with high volume. Repurchases may occur via various methods, subject to market conditions. The 52-week range is $186.05 to $282.15.

Ascendis Pharma (ASND) fell 10.9% after ending a metabolic and cardiovascular collaboration, reverting rights to TransCon semaglutide. Analysts downgraded the stock, despite a $400M share buyback plan. Investors may be reassessing the program's value and development path.